Clinical Trial Update: Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This document reports a completed Phase 2 clinical trial evaluating bavituximab in combination with paclitaxel and carboplatin for non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bavituximab (bavituximab)
• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Peregrine Pharmaceuticals | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED